Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.53 |
| ▸ | KCNN3 | Q9UGI6 | 14/20 | 0.44 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.44 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7830045 | 0.77 | PDE10A (0.53) | PDE10AKCNN3KCNN1KCNN2CRHR1 | |
| SCHEMBL12978783 | 0.76 | KCNN3 (0.40) | KCNN3 | |
| SCHEMBL15576806 | 0.72 | KCNN3 (0.49) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL7847598 | 0.71 | CDK2 (0.44) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL860305 | 0.70 | PDE10A (0.51) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL7832213 | 0.68 | LOXL2 (0.38) | PDE10AKCNN3KCNN1KCNN2CRHR1 | |
| SCHEMBL11665285 | 0.68 | PDE10A (0.38) | PDE10AKCNN3KCNN1KCNN2CRHR1 | |
| SCHEMBL1290450 | 0.67 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL30974 | 0.67 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL7821004 | 0.67 | KDM5A (0.38) | PDE10AKCNN3KCNN1KCNN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367681-B2 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | CYLENE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367681-B2 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | CYLENE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367681-B2 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | CYLENE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2432473-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | Cylene Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| WO-2010135581-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135581-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | PDE10A 1441/4885KCNN3 1339/4885KCNN1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.